CEREBEL_2B | R Documentation |
Kaplan-Meier digitized data from CEREBEL, figure 2B (PMID 25605838). A reported sample size of 540 for a primary endpoint of Incidence_CNSmets in breast cancer.
CEREBEL_2B
A data frame of 540 observations and 3 variables:
time | event time (in months) | |
event | OS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (lapatinib_cape, trastuzumab_cape) | |
Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol 2015; 33: 1564–73.
summary(CEREBEL_2B)
kmplot(CEREBEL_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.